Interchange Capital Partners LLC Has $38,000 Stock Position in CRISPR Therapeutics AG $CRSP

Key Points

• Interchange Capital Partners LLC significantly reduced its holdings in CRISPR Therapeutics AG by 89.4% in the second quarter, now holding only 786 shares valued at approximately $38,000.
• CRISPR Therapeutics reported a net loss of ($1.29) earnings per share in its latest quarterly earnings, slightly exceeding analysts' expectations, while revenue was notably lower than estimates at $0.89 million.
• Shares of CRISPR Therapeutics experienced a 3.5% increase and have a 12-month trading range of $30.04 to $78.48, with a current market capitalization of $6.53 billion.

Interchange Capital Partners LLC decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 89.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 786 shares of the company's stock after selling 6,633 shares during the quarter. Interchange Capital Partners LLC's holdings in CRISPR Therapeutics were worth $38,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of CRSP. IFP Advisors Inc boosted its holdings in CRISPR Therapeutics by 24.6% in the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after purchasing an additional 181 shares during the period. SFE Investment Counsel boosted its holdings in CRISPR Therapeutics by 5.8% in the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock valued at $221,000 after purchasing an additional 355 shares during the period. Axxcess Wealth Management LLC boosted its holdings in CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock valued at $351,000 after purchasing an additional 393 shares during the period. GF Fund Management CO. LTD. boosted its holdings in CRISPR Therapeutics by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company's stock valued at $74,000 after purchasing an additional 394 shares during the period. Finally, Ipswich Investment Management Co. Inc. boosted its holdings in CRISPR Therapeutics by 1.7% in the 2nd quarter. Ipswich Investment Management Co. Inc. now owns 24,968 shares of the company's stock valued at $1,214,000 after purchasing an additional 425 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Up 3.5%

Shares of CRSP stock opened at $71.82 on Thursday. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48. The company has a market capitalization of $6.53 billion, a P/E ratio of -13.23 and a beta of 1.84. The firm has a 50-day moving average price of $59.90 and a 200 day moving average price of $49.51.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. During the same period last year, the firm posted ($1.49) EPS. The firm's quarterly revenue was up 72.5% on a year-over-year basis. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CRSP shares. JPMorgan Chase & Co. started coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an "overweight" rating and a $70.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Chardan Capital reaffirmed a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Finally, Bank of America reduced their price objective on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Ten research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $71.71.

Insider Activity

In related news, CEO Samarth Kulkarni sold 4,242 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $282,517.20. Following the completion of the transaction, the chief executive officer directly owned 205,096 shares of the company's stock, valued at $13,659,393.60. This trade represents a 2.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at $5,554,573.20. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.